Xvivo Perfusion AB (XVIVO) - Net Assets

Latest as of June 2026: Skr2.20 Billion SEK ≈ $236.78 Million USD

Based on the latest financial reports, Xvivo Perfusion AB (XVIVO) has net assets worth Skr2.20 Billion SEK (≈ $236.78 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr2.53 Billion ≈ $271.93 Million USD) and total liabilities (Skr326.64 Million ≈ $35.15 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Xvivo Perfusion AB strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr2.20 Billion
% of Total Assets	87.07%
Annual Growth Rate	44.76%
5-Year Change	64.41%
10-Year Change	567.94%
Growth Volatility	160.82

Xvivo Perfusion AB - Net Assets Trend (2011–2025)

This chart illustrates how Xvivo Perfusion AB's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Xvivo Perfusion AB worth.

Annual Net Assets for Xvivo Perfusion AB (2011–2025)

The table below shows the annual net assets of Xvivo Perfusion AB from 2011 to 2025. Also explore XVIVO net asset momentum to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-12-31	Skr2.11 Billion ≈ $227.44 Million	-2.01%
2024-12-31	Skr2.16 Billion ≈ $232.10 Million	+10.89%
2023-12-31	Skr1.95 Billion ≈ $209.32 Million	+36.00%
2022-12-31	Skr1.43 Billion ≈ $153.91 Million	+11.26%
2021-12-31	Skr1.29 Billion ≈ $138.33 Million	+27.47%
2020-12-31	Skr1.01 Billion ≈ $108.53 Million	+74.62%
2019-12-31	Skr577.52 Million ≈ $62.15 Million	+6.85%
2018-12-31	Skr540.48 Million ≈ $58.16 Million	+7.17%
2017-12-31	Skr504.33 Million ≈ $54.27 Million	+59.39%
2016-12-31	Skr316.41 Million ≈ $34.05 Million	+71.15%
2015-12-31	Skr184.87 Million ≈ $19.90 Million	+4.93%
2014-12-31	Skr176.18 Million ≈ $18.96 Million	+82.32%
2013-12-31	Skr96.64 Million ≈ $10.40 Million	+8.87%
2012-12-31	Skr88.77 Million ≈ $9.55 Million	+645.42%
2011-12-31	Skr11.91 Million ≈ $1.28 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Xvivo Perfusion AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 2583.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	Skr316.90 Million	14.99%
Common Stock	Skr819.00K	0.04%
Other Comprehensive Income	Skr10.65 Million	0.50%
Other Components	Skr1.79 Billion	84.46%
Total Equity	Skr2.11 Billion	100.00%

Xvivo Perfusion AB Competitors by Market Cap

The table below lists competitors of Xvivo Perfusion AB ranked by their market capitalization.

Company	Market Cap
SILEX Systems Ltd AU:SLX	$849.69 Million
SK Securities Co Ltd Preference Shares KO:001515	$849.72 Million
FARO Technologies Inc NASDAQ:FARO	$849.75 Million
Sichuan Yimikang Environmental Tech Co Ltd SHE:300249	$849.93 Million
SP Group A/S CO:SPG	$849.32 Million
Entero Healthcare Solutions Ltd. NSE:ENTERO	$848.22 Million
Nuveen Select Tax-Free Income Portfolio NYSE:NXP	$848.19 Million
Shenzhen Zhongzhuang Construction Group Co Ltd SHE:002822	$847.89 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Xvivo Perfusion AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 2,156,778,000 to 2,113,458,999, a change of -43,319,001 (-2.0%).
Net income of 25,163,000 contributed positively to equity growth.
Other comprehensive income decreased equity by 81,533,999.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr25.16 Million	+1.19%
Other Comprehensive Income	Skr-81.53 Million	-3.86%
Other Changes	Skr13.05 Million	+0.62%
Total Change	Skr-	-2.01%

Book Value vs Market Value Analysis

This analysis compares Xvivo Perfusion AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.74x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 55.23x to 3.74x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2012-12-31	Skr4.54	Skr250.60	x
2013-12-31	Skr4.94	Skr250.60	x
2014-12-31	Skr8.50	Skr250.60	x
2015-12-31	Skr8.57	Skr250.60	x
2016-12-31	Skr13.89	Skr250.60	x
2017-12-31	Skr19.63	Skr250.60	x
2018-12-31	Skr20.55	Skr250.60	x
2019-12-31	Skr21.55	Skr250.60	x
2020-12-31	Skr37.11	Skr250.60	x
2021-12-31	Skr44.42	Skr250.60	x
2022-12-31	Skr48.44	Skr250.60	x
2023-12-31	Skr64.98	Skr250.60	x
2024-12-31	Skr68.11	Skr250.60	x
2025-12-31	Skr66.97	Skr250.60	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Xvivo Perfusion AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 1.19%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 3.10%
• Asset Turnover: 0.34x
• Equity Multiplier: 1.12x
Recent ROE (1.19%) is below the historical average (2.05%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2012	-0.87%	-5.22%	0.13x	1.29x	Skr-9.65 Million
2013	8.33%	11.69%	0.54x	1.32x	Skr-1.61 Million
2014	2.12%	4.41%	0.42x	1.14x	Skr-13.88 Million
2015	2.78%	4.27%	0.59x	1.10x	Skr-13.36 Million
2016	0.47%	1.09%	0.40x	1.10x	Skr-30.14 Million
2017	1.24%	4.22%	0.28x	1.07x	Skr-44.17 Million
2018	2.35%	6.75%	0.32x	1.09x	Skr-41.36 Million
2019	0.86%	2.24%	0.35x	1.10x	Skr-52.81 Million
2020	-4.34%	-24.32%	0.16x	1.14x	Skr-144.58 Million
2021	0.63%	3.15%	0.17x	1.20x	Skr-120.39 Million
2022	1.29%	4.44%	0.24x	1.21x	Skr-124.59 Million
2023	4.72%	15.37%	0.27x	1.13x	Skr-102.68 Million
2024	7.98%	20.94%	0.34x	1.11x	Skr-43.50 Million
2025	1.19%	3.10%	0.34x	1.12x	Skr-186.18 Million

Industry Comparison

This section compares Xvivo Perfusion AB's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $785,578,029
Average return on equity (ROE) among peers: -35.26%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Xvivo Perfusion AB (XVIVO)	Skr2.20 Billion	-0.87%	0.15x	$849.50 Million
Acarix A/S (ACARIX)	$51.83 Million	-148.55%	0.34x	$26.96 Million
Arcoma AB (ARCOMA)	$49.92 Million	-12.92%	0.69x	$12.26 Million
Bactiguard Holding AB (publ) (BACTI-B)	$518.71 Million	-18.32%	0.56x	$53.45 Million
BICO Group AB (BICO)	$6.80 Billion	-3.37%	0.43x	$152.02 Million
Boule Diagnostics AB (BOUL)	$300.86 Million	13.64%	0.66x	$10.78 Million
CellaVision AB (CEVI)	$8.07 Million	0.00%	2.78x	$413.26 Million
Clinical Laserthermia Systems AB (publ) (CLS-B)	$10.36 Million	-48.01%	0.14x	$9.88 Million
Chordate Medical Holding AB (CMH)	$38.95 Million	-55.88%	0.13x	$29.05K
C-Rad AB (publ) (CRAD-B)	$70.60 Million	-44.20%	0.45x	$120.99 Million
Duearity AB (DEAR)	$3.79 Million	-34.93%	0.15x	$331.97K

About Xvivo Perfusion AB

ST:XVIVO Sweden Medical Devices

Market Cap

$849.50 Million

Skr7.89 Billion SEK

Market Cap Rank

#9622 Global

#153 in Sweden

Share Price

Skr250.60

Change (1 day)

-0.79%

52-Week Range

Skr160.80 - Skr309.00

All Time High

Skr539.00